Kim S, Ghiringhelli F, de la Fouchardière C, Evesque L, Smith D, Badet N, Samalin E, Lopez-Trabada Ataz D, Parzy A, Desramé J, Baba Hamed N, Buecher B, Tougeron D, Bouché O, Dahan L, Chibaudel B, El Hajbi F, Mineur L, Dubreuil O, Ben Abdelghani M, Pecout S, Bibeau F, Herfs M, Garcia ML, Meurisse A, Vernerey D, Taïeb J, Borg C

Lancet Oncol. 2024 04;25(4):518-528

CD3-CD8 immune score associated with a clinical score stratifies PDAC prognosis regardless of adjuvant or neoadjuvant chemotherapy.

Schoumacher C, Derangère V, Gaudillière-Le Dain G, Huppe T, Rageot D, Ilie A, Vienot A, Borg C, Monnien F, Bibeau F, Truntzer C, Ghiringhelli F,

Oncoimmunology. 2023 12 21;13(1):2294563

Primary resistance to immunotherapy in patients with a dMMR/MSI metastatic gastrointestinal cancer: who is at risk? An AGEO real-world study.

Flecchia C, Auclin E, Alouani E, Mercier M, Hollebecque A, Turpin A, Mazard T, Pernot S, Dutherage M, Cohen R, Borg C, Hautefeuille V, Sclafani F, Ben-Abdelghani M, Aparicio T, De La Fouchardière C, Herve C, Perkins G, Heinrich K, Kunzmann V, Gallois C, Guimbaud R, Tougeron D, Taieb J

Br J Cancer. 2023 12 15;:

Confounding mitigation for the exposure-response relationship of bevacizumab in colorectal cancer patients.

Lobet S, Caulet M, Paintaud G, Azzopardi N, Desvignes C, Chautard R, Borg C, Capitain O, Ferru A, Bouché O, Lecomte T, Ternant D

Br J Clin Pharmacol. 2023 12 10;:

Evaluation of immune infiltrate according to the HER2 status in colorectal cancer.

Molimard C, Dor F, Overs A, Monnien F, Gessain G, Kedochim L, D'Angelo F, Abad M, Heberle M, Derangère V, Ghiringhelli F, Vuitton L, Valmary-Degano S, Borg C, Lakkis Z, Bibeau F

Dig Liver Dis. 2023 10 14;:

Time to recurrence and its relation to survival after recurrence in patients resected for stage III colon cancer.

Rasola C, Laurent-Puig P, André T, Falcoz A, Lepage C, Aparicio T, Bouché O, Lievre A, Mineur L, Bennouna J, Louvet C, Bachet JB, Borg C, Vernerey D, Lonardi S, Taieb J

Eur J Cancer. 2023 09 9;194:113321

First-line durvalumab and tremelimumab with chemotherapy in RAS-mutated metastatic colorectal cancer: a phase 1b/2 trial.

Thibaudin M, Fumet JD, Chibaudel B, Bennouna J, Borg C, Martin-Babau J, Cohen R, Fonck M, Taieb J, Limagne E, Blanc J, Ballot E, Hampe L, Bon M, Daumoine S, Peroz M, Mananet H, Derangère V, Boidot R, Michaud HA, Laheurte C, Adotevi O, Bertaut A, Truntzer C, Ghiringhelli F

Nat Med. 2023 08 10;:

Avelumab vs Standard Second-Line Chemotherapy in Patients With Metastatic Colorectal Cancer and Microsatellite Instability: A Randomized Clinical Trial.

Taïeb J, Bouche O, André T, Le Malicot K, Laurent-Puig P, Bez J, Toullec C, Borg C, Randrian V, Evesque L, Corbinais S, Perrier H, Buecher B, Di Fiore F, Gallois C, Emile JF, Lepage C, Elhajbi F, Tougeron D,

JAMA Oncol. 2023 08 3;:

Evaluation of the interest to combine a CD4 Th1-inducer cancer vaccine derived from telomerase and atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma: a randomized non-comparative phase II study (TERTIO - PRODIGE 82).

Vienot A, Jacquin M, Rebucci-Peixoto M, Pureur D, Ghiringhelli F, Assenat E, Hammel P, Rosmorduc O, Stouvenot M, Allaire M, Bouattour M, Regnault H, Fratte S, Raymond E, Soularue E, Husson-Wetzel S, Di Martino V, Muller A, Clairet AL, Fagnoni-Legat C, Adotevi O, Meurisse A, Vernerey D, Borg C

BMC Cancer. 2023 07 29;23(1):710

DCF versus doublet chemotherapy as first-line treatment of advanced squamous anal cell carcinoma: a multicenter propensity score-matching study.

Kim S, Vendrely V, Saint A, André T, Vaflard P, Samalin E, Pernot S, Bouché O, Zubir M, Desrame J, de la Fouchardière C, Smith D, Ghiringhelli F, Vienot A, Jacquin M, Klajer E, Nguyen T, François É, Taieb J, Le Malicot K, Vernerey D, Meurisse A, Borg C

Exp Hematol Oncol. 2023 07 21;12(1):63

Microfluidic device combining hydrodynamic and dielectrophoretic trapping for the controlled contact between single micro-sized objects and application to adhesion assays.

Lipp C, Koebel L, Loyon R, Bolopion A, Spehner L, Gauthier M, Borg C, Bertsch A, Renaud P

Lab Chip. 2023 07 17;:

The presence of senescent peripheral T-cells is negatively correlated to COVID-19 vaccine-induced immunity in cancer patients under 70 years of age.

Orillard E, Spehner L, Mansi L, Bouard A, Falcoz A, Lepiller Q, Renaude E, Pallandre JR, Vienot A, Kroemer M, Borg C

Front Immunol. 2023 06 2;14:1160664

Efficacy and safety of maintenance therapy with pamiparib versus placebo for advanced gastric cancer responding to first-line platinum-based chemotherapy: Phase 2 study results.

Ciardiello F, Bang YJ, Cervantes A, Dvorkin M, Lopez CD, Metges JP, Sánchez Ruiz A, Calvo M, Strickland AH, Kannourakis G, Muro K, Kawakami H, Wei J, Borg C, Zhu Z, Gupta N, Pelham RJ, Shen L

Cancer Med. 2023 06 1;:

Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER PRODIGE 23): Health-related quality of life longitudinal analysis.

Bascoul-Mollevi C, Gourgou S, Borg C, Etienne PL, Rio E, Rullier E, Juzyna B, Castan F, Conroy T

Eur J Cancer. 2023 03 24;186:151-165

CD8 CD226 T cells in liver metastases dictate the prognosis of colorectal cancer patients treated with chemotherapy and radical surgery.

Viot J, Abdeljaoued S, Vienot A, Seffar E, Spehner L, Bouard A, Asgarov K, Pallandre JR, Renaude E, Klajer E, Molimard C, Monnien F, Bibeau F, Turco C, Heyd B, Peixoto P, Hervouet E, Loyon R, Doussot A, Borg C, Kroemer M

Cell Mol Immunol. 2023 01 30;:

SALL4-related gene signature defines a specific stromal subset of pancreatic ductal adenocarcinoma with poor prognostic features.

Vienot A, Monnien F, Truntzer C, Mougey V, Bouard A, Pallandre JR, Molimard C, Loyon R, Asgarov K, Averous G, Ghiringhelli F, Bibeau F, Peixoto P, Borg C

Mol Oncol. 2023 01 1;:

Modified DCF (Docetaxel, Cisplatin and 5-fluorouracil) chemotherapy is effective for the treatment of advanced rectal squamous cell carcinoma.

Hervé L, Kim S, Boustani J, Klajer E, Pernot M, Nguyen T, Lakkis Z, Borg C, Vienot A

Front Oncol. 2022 11 17;12:974108

Chemokine switch regulated by TGF-β1 in cancer-associated fibroblast subsets determines the efficacy of chemo-immunotherapy.

Vienot A, Pallandre JR, Renaude E, Viot J, Bouard A, Spehner L, Kroemer M, Abdeljaoued S, van der Woning B, de Haard H, Loyon R, Hervouet E, Peixoto P, Borg C

Oncoimmunology. 2022 11 12;11(1):2144669

Prognostic role of HPV integration status and molecular profile in advanced anal carcinoma: An ancillary study to the epitopes-HPV02 trial.

Debernardi A, Meurisse A, Prétet JL, Guenat D, Monnien F, Spehner L, Vienot A, Roncarati P, André T, Abramowitz L, Molimard C, Mougin C, Herfs M, Kim S, Borg C

Front Oncol. 2022 10 14;12:941676

Bemarituzumab in patients with FGFR2b-selected gastric or gastro-oesophageal junction adenocarcinoma (FIGHT): a randomised, double-blind, placebo-controlled, phase 2 study.

Wainberg ZA, Enzinger PC, Kang YK, Qin S, Yamaguchi K, Kim IH, Saeed A, Oh SC, Li J, Turk HM, Teixeira A, Borg C, Hitre E, Udrea AA, Cardellino GG, Sanchez RG, Collins H, Mitra S, Yang Y, Catenacci DVT, Lee KW

Lancet Oncol. 2022 10 13;:

Safety, Immunogenicity, and 1-Year Efficacy of Universal Cancer Peptide-Based Vaccine in Patients With Refractory Advanced Non-Small-Cell Lung Cancer: A Phase Ib/Phase IIa De-Escalation Study.

Adotévi O, Vernerey D, Jacoulet P, Meurisse A, Laheurte C, Almotlak H, Jacquin M, Kaulek V, Boullerot L, Malfroy M, Orillard E, Eberst G, Lagrange A, Favier L, Gainet-Brun M, Doucet L, Teixeira L, Ghrieb Z, Clairet AL, Guillaume Y, Kroemer M, Hocquet D, Moltenis M, Limat S, Quoix E, Mascaux C, Debieuvre D, Fagnoni-Legat C, Borg C, Westeel V

J Clin Oncol. 2022 09 7;:JCO2200096

Phase II INTERACT-ION study: ezabenlimab (BI 754091) and mDCF (docetaxel, cisplatin, and 5-fluorouracil) followed by chemoradiotherapy in patients with Stage III squamous cell anal carcinoma.

Kim S, Boustani J, Vernerey D, Vendrely V, Evesque L, Francois E, Quero L, Ghiringhelli F, de la Fouchardière C, Dahan L, Bouché O, Chibaudel B, Hajbi FE, Vernet C, Rebucci-Peixoto M, Feuersinger A, Maritaz C, Borg C

Front Oncol. 2022 08 24;12:918499

Could 18-FDG PET-CT Radiomic Features Predict the Locoregional Progression-Free Survival in Inoperable or Unresectable Oesophageal Cancer?

De Bari B, Lefevre L, Henriques J, Gatta R, Falcoz A, Mathieu P, Borg C, Dinapoli N, Boulahdour H, Boldrini L, Valentini V, Vernerey D

Cancers (Basel). 2022 08 22;14(16):

Long-Term Disease Control After locoregional Pelvic Chemoradiation in Patients with Advanced Anal Squamous Cell Carcinoma.

Grave A, Blanc J, De Bari B, Pernot M, Boulbair F, Noirclerc M, Vienot A, Kim S, Borg C, Boustani J

Front Oncol. 2022 07 22;12:918271

A Phase II Study Evaluating the Interest to Combine UCPVax, a Telomerase CD4 T1-Inducer Cancer Vaccine, and Atezolizumab for the Treatment of HPV Positive Cancers: VolATIL Study.

Rebucci-Peixoto M, Vienot A, Adotevi O, Jacquin M, Ghiringhelli F, de la Fouchardière C, You B, Maurina T, Kalbacher E, Bazan F, Meynard G, Clairet AL, Fagnoni-Legat C, Spehner L, Bouard A, Vernerey D, Meurisse A, Kim S, Borg C, Mansi L

Front Oncol. 2022 07 19;12:957580

Impact of trough concentrations of regorafenib and its major metabolites M-2 and M-5 on overall survival of chemorefractory metastatic colorectal cancer patients: Results from a multicentre GERCOR TEXCAN phase II study.

Rousseau B, Boukerma AK, Henriques J, Cohen R, Lucidarme O, Borg C, Tournigand C, Kim S, Bachet JB, Mazard T, Louvet C, Chibaudel B, Vernerey D, Andre T, Hulin A

Eur J Cancer. 2022 Apr 27;168:99-107

Tislelizumab Versus Chemotherapy as Second-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma (RATIONALE-302): A Randomized Phase III Study.

Shen L, Kato K, Kim SB, Ajani JA, Zhao K, He Z, Yu X, Shu Y, Luo Q, Wang J, Chen Z, Niu Z, Zhang L, Yi T, Sun JM, Chen J, Yu G, Lin CY, Hara H, Bi Q, Satoh T, Pazo-Cid R, Arkenau HT, Borg C, Lordick F, Li L, Ding N, Tao A, Shi J, Van Cutsem E,

J Clin Oncol. 2022 Apr 20;:JCO2101926

First-line trifluridine/tipiracil + bevacizumab in patients with unresectable metastatic colorectal cancer: final survival analysis in the TASCO1 study.

Van Cutsem E, Danielewicz I, Saunders MP, Pfeiffer P, Argilés G, Borg C, Glynne-Jones R, Punt CJA, Van de Wouw AJ, Fedyanin M, Stroyakovskiy D, Kroening H, Garcia-Alfonso P, Wasan H, Falcone A, Fougeray R, Egorov A, Amellal N, Moiseyenko V

Br J Cancer. 2022 Apr 19;:

Tissue-resident memory T cells in gastrointestinal cancer immunology and immunotherapy: ready for prime time?

Abdeljaoued S, Arfa S, Kroemer M, Ben Khelil M, Vienot A, Heyd B, Loyon R, Doussot A, Borg C

J Immunother Cancer. 2022 Apr;10(4):

Low correlation between Ki67 assessed by qRT-PCR in Oncotype Dx score and Ki67 assessed by Immunohistochemistry.

Selmani Z, Molimard C, Overs A, Bazan F, Chaigneau L, Dobi E, Meneveau N, Mansi L, Paillard MJ, Meynard G, Viot J, Algros MP, Borg C, Feugeas JP, Pivot X, Prétet JL, Curtit E

Sci Rep. 2022 Mar 7;12(1):3617

Impact of the COVID-19 pandemic on disease stage and treatment for patients with pancreatic adenocarcinoma: A French comprehensive multicentre ambispective observational cohort study (CAPANCOVID).

Brugel M, Letrillart L, Evrard C, Thierry A, Tougeron D, El Amrani M, Piessen G, Truant S, Turpin A, d'Engremont C, Roth G, Hautefeuille V, Regimbeau JM, Williet N, Schwarz L, Di Fiore F, Borg C, Doussot A, Lambert A, Moulin V, Trelohan H, Bolliet M, Topolscki A, Ayav A, Lopez A, Botsen D, Piardi T, Carlier C, Bouché O

Eur J Cancer. 2022 Feb 10;166:8-20

Harnessing Antitumor CD4 T Cells for Cancer Immunotherapy.

Ben Khelil M, Godet Y, Abdeljaoued S, Borg C, Adotévi O, Loyon R

Cancers (Basel). 2022 Jan 5;14(1):

Second-line treatment after docetaxel, cisplatin and 5-fluorouracil in metastatic squamous cell carcinomas of the anus. Pooled analysis of prospective Epitopes-HPV01 and Epitopes-HPV02 studies.

Stouvenot M, Meurisse A, Saint A, Buecher B, André T, Samalin E, Jary M, El Hajbi F, Baba-Hamed N, Pernot S, Kaminsky MC, Bouché O, Desrame J, Zoubir M, Smith D, Ghiringhelli F, Parzy A, de la Fouchardiere C, Almotlak H, Vienot A, Jacquin M, Taieb J, Nguyen T, Vernerey D, Borg C, Kim S

Eur J Cancer. 2022 Jan 4;162:138-147

Interest of the Addition of Taxanes to Standard Treatment in First-Line Advanced HER2 Positive Gastroesophageal Adenocarcinoma in Selective Patients.

Orillard E, Henriques J, Vernerey D, Almotlak H, Calcagno F, Fein F, Fratté S, Jary M, Klajer E, Vienot A, Borg C, Kim S

Front Oncol. 2022 ;12:763926

The immune microenvironment in patients with mismatch-repair-proficient oligometastatic colorectal cancer exposed to chemotherapy: the randomized MIROX GERCOR cohort study.

Jary M, Liu WW, Yan D, Bai I, Muranyi A, Colle E, Brocheriou I, Turpin A, Radosevic-Robin N, Bourgoin P, Penault-Llorca F, Cohen R, Vernerey D, André T, Borg C, Shanmugam K, Svrcek M

Mol Oncol. 2021 Dec 25;:

A new workflow combining magnetic cell separation and impedance-based cell dispensing for gentle, simple and reliable cloning of specific CD8+ T cells.

Ben Khelil M, Aeberli L, Perchaud M, Genolet R, Abdeljaoued S, Borg C, Binda D, Harari A, Jandus C, Muller G, Loyon R

SLAS Technol. 2021 Dec 4;:

Selecting the right chemotherapy in first line advanced squamous cell carcinoma of the anus.

Ducreux M, Kim S, Borg C

Ann Oncol. 2021 Nov 26;:

Cusatuzumab for treatment of CD70-positive relapsed or refractory cutaneous T-cell lymphoma.

Leupin N, Zinzani PL, Morschhauser F, Dalle S, Maerevoet M, Michot JM, Ribrag V, Offner F, Beylot-Barry M, Moins-Teisserenc H, Zwaenepoel K, de Winne K, Battistella M, Hultberg A, Gandini D, Moshir M, Jacobs J, Delahaye T, Khan A, Zabrocki P, Silence K, van Rompaey L, Borg C, Motta G, Melle F, Calleri A, Pauwels P, de Haard H, Pileri S, Bagot M

Cancer. 2021 Nov 2;:

Homeostatic cytokines tune naivety and stemness of cord blood-derived transgenic T cells.

Marton C, Mercier-Letondal P, Loyon R, Adotévi O, Borg C, Galaine J, Godet Y

Cancer Gene Ther. 2021 Oct 13;:

Health-Related Quality of Life Analysis in Metastatic Colorectal Cancer Patients Treated by Second-Line Chemotherapy, Associated With Either Cetuximab or Bevacizumab: The PRODIGE 18 Randomized Phase II Study.

Bertaut A, Touchefeu Y, Blanc J, Bouché O, François E, Conroy T, Artru P, Adenis A, Gobbo J, Borg C, Ghiringhelli F, Bennouna J

Clin Colorectal Cancer. 2021 Oct 3;:

Present and Future Research on Anal Squamous Cell Carcinoma.

Spehner L, Boustani J, Cabel L, Doyen J, Vienot A, Borg C, Kim S

Cancers (Basel). 2021 Aug 2;13(15):

The NHance Mutation-Equipped Anti-MET Antibody ARGX-111 Displays Increased Tissue Penetration and Anti-Tumor Activity in Advanced Cancer Patients.

Aftimos P, Rolfo C, Rottey S, Barthélémy P, Borg C, Park K, Oh DY, Kim SW, De Jonge N, Hanssens V, Zwanenpoel K, Molthoff C, Vugts D, Dreier T, Verheesen P, van Dongen GAMS, Jacobs J, Van Rompaey L, Hultberg A, Michieli P, Pauwels P, Fung S, Thibault A, de Haard H, Leupin N, Awada A

Biomedicines. 2021 Jun 10;9(6):

Real-world safety and effectiveness of regorafenib in metastatic colorectal cancer: the French CORRELATE cohort.

Metges JP, Genet D, Tougeron D, Ligeza C, Ducreux M, Borg C, Guimbaud R, Phelip JM, Dourthe LM, Kim S

Future Oncol. 2021 May 20;:

PPARɣ drives IL-33-dependent ILC2 pro-tumoral functions.

Ercolano G, Gomez-Cadena A, Dumauthioz N, Vanoni G, Kreutzfeldt M, Wyss T, Michalik L, Loyon R, Ianaro A, Ho PC, Borg C, Kopf M, Merkler D, Krebs P, Romero P, Trabanelli S, Jandus C

Nat Commun. 2021 05 5;12(1):2538

Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial.

Conroy T, Bosset JF, Etienne PL, Rio E, François É, Mesgouez-Nebout N, Vendrely V, Artignan X, Bouché O, Gargot D, Boige V, Bonichon-Lamichhane N, Louvet C, Morand C, de la Fouchardière C, Lamfichekh N, Juzyna B, Jouffroy-Zeller C, Rullier E, Marchal F, Gourgou S, Castan F, Borg C,

Lancet Oncol. 2021 Apr 13;:

Study of the SARS-CoV-2-specific immune T-cell responses in COVID-19-positive cancer patients.

Mansi L, Spehner L, Daguindau E, Bouiller K, Almotlak H, Stein U, Bouard A, Kim S, Klajer E, Jary M, Meynard G, Vienot A, Nardin C, Bazan F, Lepiller Q, Westeel V, Adotévi O, Borg C, Kroemer M

Eur J Cancer. 2021 Mar 26;150:1-9

[Squamous cell anal carcinoma. What's next ?]

Kim S, Spehner L, Cabel L, Bidard FC, Borg C

Bull Cancer. 2021 Jan 7;:

Feasibility of health-related quality of life (HRQoL) assessment for cancer patients using electronic patient-reported outcome (ePRO) in daily clinical practice.

Mouillet G, Falcoz A, Fritzsch J, Almotlak H, Jacoulet P, Pivot X, Villanueva C, Mansi L, Kim S, Curtit E, Meneveau N, Adotevi O, Jary M, Eberst G, Vienot A, Calcagno F, Pozet A, Djoumakh O, Borg C, Westeel V, Anota A, Paget-Bailly S

Qual Life Res. 2021 Jan 2;:

Additive Value of Preoperative Sarcopenia and Lymphopenia for Prognosis Prediction in Localized Pancreatic Ductal Adenocarcinoma.

d'Engremont C, Grillot J, Raillat J, Vernerey D, Vuitton L, Koch S, Turco C, Heyd B, Mouillet G, Jacquinot Q, Borg C, Vienot A

Front Oncol. 2021 ;11:683289

Epigenetic Reprogramming of CD4 Helper T Cells as a Strategy to Improve Anticancer Immunotherapy.

Renaude E, Kroemer M, Borg C, Peixoto P, Hervouet E, Loyon R, Adotévi O

Front Immunol. 2021 ;12:669992

Severe COVID-19 patients exhibit an ILC2 NKG2D population in their impaired ILC compartment.

Gomez-Cadena A, Spehner L, Kroemer M, Khelil MB, Bouiller K, Verdeil G, Trabanelli S, Borg C, Loyon R, Jandus C

Cell Mol Immunol. 2020 Dec 14;:

EZH2 and KDM6B Expressions Are Associated with Specific Epigenetic Signatures during EMT in Non Small Cell Lung Carcinomas.

Lachat C, Bruyère D, Etcheverry A, Aubry M, Mosser J, Warda W, Herfs M, Hendrick E, Ferrand C, Borg C, Delage-Mourroux R, Feugeas JP, Guittaut M, Hervouet E, Peixoto P

Cancers (Basel). 2020 Dec 5;12(12):

Investigation of the prognostic value of CD4 T cell subsets expanded from tumor-infiltrating lymphocytes of colorectal cancer liver metastases.

Kroemer M, Turco C, Spehner L, Viot J, Idirène I, Bouard A, Renaude E, Deschamps M, Godet Y, Adotévi O, Limat S, Heyd B, Jary M, Loyon R, Borg C

J Immunother Cancer. 2020 Nov;8(2):

RECIST and iRECIST criteria for the evaluation of nivolumab plus ipilimumab in patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: the GERCOR NIPICOL phase II study.

Cohen R, Bennouna J, Meurisse A, Tournigand C, De La Fouchardière C, Tougeron D, Borg C, Mazard T, Chibaudel B, Garcia-Larnicol ML, Svrcek M, Vernerey D, Menu Y, André T

J Immunother Cancer. 2020 Nov;8(2):

How to Choose the Right Treatment for Patients With Advanced Squamous Cell Carcinoma in the Absence of a Comparative Randomized Clinical Trial.

Kim S, Vernerey D, Borg C

J Clin Oncol. 2020 Oct 7;:JCO2002137

Anti-Telomerase CD4 Th1 Immunity and Monocytic-Myeloid-Derived-Suppressor Cells Are Associated with Long-Term Efficacy Achieved by Docetaxel, Cisplatin, and 5-Fluorouracil (DCF) in Advanced Anal Squamous Cell Carcinoma: Translational Study of Epitopes-HPV

Spehner L, Kim S, Vienot A, François E, Buecher B, Adotevi O, Vernerey D, Abdeljaoued S, Meurisse A, Borg C

Int J Mol Sci. 2020 Sep 17;21(18):

Preoperative immunotherapy for resectable hepatocellular carcinoma: Toward a paradigm shift?

Seckler F, Doussot A, Colpart P, Turco C, Calame P, Aubin F, Algros MP, Borg C, Nardin C, Heyd B

J. Hepatol.. 2020 Sep 17;:

FOLFIRINOX de-escalation in advanced pancreatic cancer: a multicenter real-life study.

Chevalier H, Vienot A, Lièvre A, Edeline J, El Hajbi F, Peugniez C, Vernerey D, Meurisse A, Hammel P, Neuzillet C, Borg C, Turpin A

Oncologist. 2020 Sep 4;:

COVID-19 patients display distinct SARS-CoV-2 specific T-cell responses according to disease severity.

Kroemer M, Spehner L, Vettoretti L, Bouard A, Eberst G, Floury SP, Capellier G, Lepiller Q, Orillard E, Mansi L, Clairet AL, Westeel V, Limat S, Dubois M, Malinowski L, Bohard L, Borg C, Chirouze C, Bouiller K

J. Infect.. 2020 Aug 24;:

Exposure-Response Analysis of Raltitrexed Assessing Liver Toxicity.

Royer B, Schmitt A, Nguyen T, Paillard MJ, Jary M, Demarchi M, Vernerey D, Henriques J, Jacquin M, Borg C, Kim S

Br J Clin Pharmacol. 2020 Aug 12;:

Effect of trifluridine/tipiracil in patients treated in RECOURSE by prognostic factors at baseline: an exploratory analysis.

Tabernero J, Argiles G, Sobrero AF, Borg C, Ohtsu A, Mayer RJ, Vidot L, Moreno Vera SR, Van Cutsem E

ESMO Open. 2020 Aug;5(4):

Economic evaluations of cancer immunotherapy: a systematic review and quality evaluation.

Couchoud C, Fagnoni P, Aubin F, Westeel V, Maurina T, Thiery-Vuillemin A, Gerard C, Kroemer M, Borg C, Limat S, Nerich V

Cancer Immunol. Immunother.. 2020 Jul 16;:

Trifluridine/Tipiracil plus Bevacizumab in Patients with Untreated Metastatic Colorectal Cancer Ineligible for Intensive Therapy: the Randomized TASCO1 Study.

Ann. Oncol.. 2020 Jun 1;:

Atezolizumab plus modified docetaxel-cisplatin-5-fluorouracil (mDCF) regimen versus mDCF in patients with metastatic or unresectable locally advanced recurrent anal squamous cell carcinoma: a randomized, non-comparative phase II SCARCE GERCOR trial.

Kim S, Buecher B, André T, Jary M, Bidard FC, Ghiringhelli F, François É, Taieb J, Smith D, de la Fouchardière C, Desramé J, Samalin E, Parzy A, Baba-Hamed N, Bouché O, Tougeron D, Dahan L, El Hajbi F, Jacquin M, Rebucci-Peixoto M, Spehner L, Vendrely V, Vernerey D, Borg C

BMC Cancer. 2020 Apr 25;20(1):352

Prognostic and predictive value of the Immunoscore in stage III colon cancer patients treated with oxaliplatin in the prospective IDEA France PRODIGE-GERCOR cohort study.

Pagès F, André T, Taieb J, Vernerey D, Henriques J, Borg C, Marliot F, Ben Jannet R, Louvet C, Mineur L, Bennouna J, Desrame J, Faroux R, Kirilovsky A, Duval A, Laurent-Puig P, Svrcek M, Hermitte F, Catteau A, Galon J, Emile JF

Ann. Oncol.. 2020 Apr 12;:

Ramucirumab in elderly patients with hepatocellular carcinoma and elevated alpha-fetoprotein after sorafenib in REACH and REACH-2.

Kudo M, Galle PR, Llovet JM, Finn RS, Vogel A, Motomura K, Assenat E, Merle P, Brandi G, Daniele B, Okusaka T, Tomášek J, Borg C, Dadduzio V, Morimoto M, Pracht M, Jen MH, Ubreva ND, Widau RC, Shinozaki K, Yoshikawa R, Zhu AX

Liver Int.. 2020 Apr 12;:

Molecular description of ANGPT2 associated colorectal carcinoma.

Jary M, Hasanova R, Vienot A, Asgarov K, Loyon R, Tirole C, Bouard A, Orillard E, Klajer E, Kim S, Viot J, Colle E, Adotevi O, Bouché O, Lecomte T, Borg C, Feugeas JP

Int. J. Cancer. 2020 Mar 29;:

FOLFOXIRI FOLFIRINOX as first-line chemotherapy in patients with advanced pancreatic cancer: A population-based cohort study.

Vienot A, Chevalier H, Bolognini C, Gherga E, Klajer E, Meurisse A, Jary M, Kim S, d'Engremont C, Nguyen T, Calcagno F, Almotlak H, Fein F, Nasri M, Abdeljaoued S, Turpin A, Borg C, Vernerey D

World J Gastrointest Oncol. 2020 Mar 15;12(3):332-346

The Fate of Th17 Cells is Shaped by Epigenetic Modifications and Remodeled by the Tumor Microenvironment.

Renaude E, Kroemer M, Loyon R, Binda D, Borg C, Guittaut M, Hervouet E, Peixoto P

Int J Mol Sci. 2020 Feb 29;21(5):

Concurrent losses of skeletal muscle mass, adipose tissue and bone mineral density during bevacizumab / cytotoxic chemotherapy treatment for metastatic colorectal cancer.

Dolly A, Lecomte T, Bouché O, Borg C, Terrebonne E, Douillard JY, Chautard R, Raoul W, Ternant D, Leger J, Bleuzen A, Dumas JF, Servais S, Baracos VE

Clin Nutr. 2020 Feb 22;:

[Localized MSI/dMMR gastric cancer patients, perioperative immunotherapy instead of chemotherapy: The GERCOR NEONIPIGA phase II study is opened to recruitment].

Cohen R, Pudlarz T, Garcia-Larnicol ML, Vernerey D, Dray X, Clavel L, Jary M, Piessen G, Zaanan A, Aparicio T, Louvet C, Tournigand C, Chibaudel B, Tougeron D, Guimbaud R, Benouna J, Adenis A, Sokol H, Borg C, Duval A, Svrcek M, André T

Bull Cancer. 2020 Feb 10;:

Nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer (LAPACT): a multicentre, open-label phase 2 study.

Philip PA, Lacy J, Portales F, Sobrero A, Pazo-Cid R, Manzano Mozo JL, Kim EJ, Dowden S, Zakari A, Borg C, Terrebonne E, Rivera F, Sastre J, Bathini V, López-Trabada D, Asselah J, Saif MW, Shiansong Li J, Ong TJ, Nydam T, Hammel P

Lancet Gastroenterol Hepatol. 2020 Jan 14;:

Implementation and use of whole exome sequencing in daily practice for metastatic solid cancer.

Réda M, Richard C, Bertaut A, Niogret J, Collot T, Fumet JD, Blanc J, Truntzer C, Desmoulins I, Ladoire S, Hennequin A, Favier L, Bengrine L, Vincent J, Hervieu A, Dusserre JG, Lepage C, Foucher P, Borg C, Albuisson J, Arnould L, Nambot S, Faivre L, Boidot R, Ghiringhelli F

EBioMedicine. 2020 Jan 7;51:102624

Pooled analysis of 115 patients from updated data of Epitopes-HPV01 and Epitopes-HPV02 studies in first-line advanced anal squamous cell carcinoma.

Kim S, Meurisse A, Spehner L, Stouvenot M, François E, Buecher B, André T, Samalin E, Jary M, Nguyen T, El Hajbi F, Baba-Hamed N, Pernot S, Kaminsky MC, Bouché O, Desrame J, Zoubir M, Ghiringhelli F, Parzy A, de la Fouchardiere C, Boulbair F, Lakkis Z, Klajer E, Jacquin M, Taieb J, Vendrely V, Vernerey D, Borg C

Ther Adv Med Oncol. 2020 ;12:1758835920975356

Nal-IRI/LV5-FU versus paclitaxel as second-line therapy in patients with metastatic esophageal squamous cell carcinoma (OESIRI)-PRODIGE 62: A multicentre, randomised, non-comparative phase II study.

Randrian V, Adenis A, Desrame J, Barbier E, Di Fiore F, Lièvre A, Dahan L, Laurent-Puig P, Mineur L, Breysacher G, Roquin G, Louafi S, Lopez A, Louvet C, Borg C, Metges JP, Faroux R, Gaba L, Manfredi S, Tougeron D

Dig Liver Dis. 2019 Dec 30;:

Immunoregulation and Clinical Implications of ANGPT2/TIE2+ M-MDSC Signature in Non-Small Cell Lung Cancer.

Lauret Marie Joseph E, Laheurte C, Jary M, Boullerot L, Asgarov K, Gravelin E, Bouard A, Rangan L, Dosset M, Borg C, Adotévi O

Cancer Immunol Res. 2019 Dec 23;:

Metronomic cyclophosphamide induces regulatory T cells depletion and PSA specific T cells reactivation in patients with biochemical recurrent prostate cancer.

Laheurte C, Thiery-Vuillemin A, Calcagno F, Legros A, Simonin H, Boullerot L, Jacquin M, Nguyen T, Mouillet G, Borg C, Adotévi O

Int. J. Cancer. 2019 Nov 20;:

[Radiologic response assessment in metastatic colorectal cancers].

Fabre A, Badet N, Calame P, Delabrousse E, Wespiser M, Turco C, Borg C, Jary M

Bull Cancer. 2019 Sep 27;:

CD4 T cells target colorectal cancer antigens upregulated by oxaliplatin.

Galaine J, Turco C, Vauchy C, Royer B, Mercier-Letondal P, Queiroz L, Loyon R, Mouget V, Boidot R, Laheurte C, Lakkis Z, Jary M, Adotévi O, Borg C, Godet Y

Int. J. Cancer. 2019 Aug 9;:

Comparison of Molecular and Histologic Ultrastaging Methods in Sentinel Lymph Node Analysis from Clinical Stage II Colon Cancers.

Deroo O, Lakkis Z, Paquette B, Grand D, Monnien F, Felix S, Borg C, Heyd B, Kim S, Valmary-Degano S

Appl. Immunohistochem. Mol. Morphol.. 2019 Aug;27(7):e65-e70

Hepatic arterial chemotherapy with raltitrexed and oxaliplatin versus standard chemotherapy in unresectable liver metastases from colorectal cancer after conventional chemotherapy failure (HEARTO): a randomized phase-II study.

Ghiringhelli F, Vincent J, Bengrine L, Borg C, Jouve JL, Loffroy R, Guiu B, Blanc J, Bertaut A

J. Cancer Res. Clin. Oncol.. 2019 Jul 4;:

Infiltrating and peripheral immune cell analysis in advanced gastric cancer according to the Lauren classification and its prognostic significance.

Pernot S, Terme M, Radosevic-Robin N, Castan F, Badoual C, Marcheteau E, Penault-Llorca F, Bouche O, Bennouna J, Francois E, Ghiringhelli F, De La Fouchardiere C, Samalin E, Baptiste Bachet J, Borg C, Boige V, Voron T, Stanbury T, Tartour E, Gourgou S, Malka D, Taieb J

Gastric Cancer. 2019 Jul 2;:

Ramucirumab and paclitaxel in patients with gastric cancer and prior trastuzumab: subgroup analysis from RAINBOW study.

De Vita F, Borg C, Farina G, Geva R, Carton I, Cuku H, Wei R, Muro K

Future Oncol. 2019 Jun 25;:

FOLFOX alone or combined with rilotumumab or panitumumab as first-line treatment for patients with advanced gastroesophageal adenocarcinoma (PRODIGE 17-ACCORD 20-MEGA): a randomised, open-label, three-arm phase II trial.

Malka D, François E, Penault-Llorca F, Castan F, Bouché O, Bennouna J, Ghiringhelli F, Fouchardière C, Borg C, Samalin E, Bachet JB, Raoul JL, Miglianico L, Bengrine-Lefèvre L, Dahan L, Lecaille C, Aparicio T, Stanbury T, Perrier H, Cayre A, Laurent-Puig P, Gourgou S, Emile JF, Taïeb J

Eur. J. Cancer. 2019 May 23;115:97-106

Morbidity and oncological outcomes of rectal cancer impaired by previous prostate malignancy.

Lakkis Z, Vernerey D, Mege D, Faucheron JL, Panis Y, Tuech JJ, Lefevre JH, Brouquet A, Dumont F, Borg C, Woronoff AS, Meurisse A, Heyd B, Rullier E,

Br J Surg. 2019 May 10;:

Efficacy and Safety of Two Neoadjuvant Strategies With Bevacizumab in MRI-Defined Locally Advanced T3 Resectable Rectal Cancer: Final Results of a Randomized, Noncomparative Phase 2 INOVA Study.

Borg C, Mantion G, Boudghène F, Mornex F, Ghiringhelli F, Adenis A, Azria D, Balosso J, Ben Abdelghani M, Bachet JB, Vendrely V, François Y, Conroy T, Rio E, Roullet B, Spaëth D, Quero L, Lakkis Z, Coudert M, Ionescu-Goga M, Tanang A, André T

Clin Colorectal Cancer. 2019 May 3;:

Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: results from the phase II nonrandomized KEYNOTE-059 study.

Bang YJ, Kang YK, Catenacci DV, Muro K, Fuchs CS, Geva R, Hara H, Golan T, Garrido M, Jalal SI, Borg C, Doi T, Yoon HH, Savage MJ, Wang J, Dalal RP, Shah S, Wainberg ZA, Chung HC

Gastric Cancer. 2019 Mar 25;:

EMT is associated with an epigenetic signature of ECM remodeling genes.

Peixoto P, Etcheverry A, Aubry M, Missey A, Lachat C, Perrard J, Hendrick E, Delage-Mourroux R, Mosser J, Borg C, Feugeas JP, Herfs M, Boyer-Guittaut M, Hervouet E

Cell Death Dis. 2019 Feb 27;10(3):205

Circulating NKp46 Natural Killer cells have a potential regulatory property and predict distinct survival in Non-Small Cell Lung Cancer.

Picard E, Godet Y, Laheurte C, Dosset M, Galaine J, Beziaud L, Loyon R, Boullerot L, Lauret Marie Joseph E, Spehner L, Jacquin M, Eberst G, Gaugler B, Le Pimpec-Barthes F, Fabre E, Westeel V, Caignard A, Borg C, Adotévi O

Oncoimmunology. 2019 ;8(2):e1527498

Peripheral Innate Lymphoid Cells Are Increased in First Line Metastatic Colorectal Carcinoma Patients: A Negative Correlation With Th1 Immune Responses.

Loyon R, Jary M, Salomé B, Gomez-Cadena A, Galaine J, Kroemer M, Romero P, Trabanelli S, Adotévi O, Borg C, Jandus C

Front Immunol. 2019 ;10:2121

Is Overexpressed in Triple Negative Breast Cancer and Its In Vitro Extinction Leads to the Inhibition of Pro-Cancer Phenotypes.

Claude-Taupin A, Fonderflick L, Gauthier T, Mansi L, Pallandre JR, Borg C, Perez V, Monnien F, Algros MP, Vigneron M, Adami P, Delage-Mourroux R, Peixoto P, Herfs M, Boyer-Guittaut M, Hervouet E

Cells. 2018 Dec 6;7(12):

Biologie, concepts et principes des CAR-T cells

Rubio MT, Galaine J, Borg C, Daguindau É

Bull Cancer. 2018 Dec;105 Suppl 2:S135-S146

Clinical validity of HPV circulating tumor DNA in advanced anal carcinoma: an ancillary study to the Epitopes-HPV02 trial.

Bernard-Tessier A, Jeannot E, David G, Debernardi A, Michel M, Proudhon C, Vincent-Salomon A, Bieche I, Pierga JY, Buecher B, Meurisse A, François E, Cohen R, Jary M, Vendrely V, Samalin E, El Hajbi F, Baba-Hamed N, Borg C, Bidard FC, Kim S

Clin. Cancer Res.. 2018 Nov 30;:

Continuation of Bevacizumab vs Cetuximab Plus Chemotherapy After First Progression in KRAS Wild-Type Metastatic Colorectal Cancer: The UNICANCER PRODIGE18 Randomized Clinical Trial.

Bennouna J, Hiret S, Bertaut A, Bouché O, Deplanque G, Borel C, François E, Conroy T, Ghiringhelli F, des Guetz G, Seitz JF, Artru P, Hebbar M, Stanbury T, Denis MG, Adenis A, Borg C

JAMA Oncol. 2018 Oct 25;:

Personalized identification of tumor-associated immunogenic neoepitopes in hepatocellular carcinoma in complete remission after sorafenib treatment.

Vrecko S, Guenat D, Mercier-Letondal P, Faucheu H, Dosset M, Royer B, Galaine J, Boidot R, Kim S, Jary M, Adotévi O, Borg C, Godet Y

Oncotarget. 2018 Oct 23;9(83):35394-35407

Droplet digital PCR of circulating tumour DNA for the detection of RAS/BRAF mutation in metastatic colorectal cancer.

Van Cutsem E, Lesniewski-Kmak K, Saunders MP, Wasan H, Argiles G, Borg C, Creemers GM, Fedyanin M, Glynne-Jones R, Pfeiffer P, Punt CJA, Stroyakovskiy D, Ten Tije AJ, van de Wouw A, Cattan V, Desachy G, Amellal N, Moiseyenko VM

Ann. Oncol.. 2018 Oct;29 Suppl 8:viii181

HPV circulating tumor DNA as predictive biomarker of sustained response to chemotherapy in advanced anal carcinoma.

Bernard-Tessier A, Jeannot E, Guenat D, Michel M, Proudhon C, Vincent-Salomon A, Bièche I, Pierga JY, Buecher B, Francois E, Kim S, André T, Jary M, Vendrely V, Samalin E, El Hajbi F, Baba-Hamed N, Meurisse A, Bidard FC, Borg C

Ann. Oncol.. 2018 Oct;29 Suppl 8:viii29

The level of circulating NKp46+ CD56dim CD16+ natural killer cells predicts distinct survival in non-small cell lung cancer.

Picard E, Godet Y, Laheurte C, Boullerot L, Lauret Marie Joseph E, Jacquin M, Kaulek V, Eberst G, Gaugler B, Jacoulet P, Gainet-Brun M, Lahoucarde J, Almotlak H, Le Pimpec-Barthes F, Fabre-Guillevin E, Borg C, Westeel V, Adotevi O

Ann. Oncol.. 2018 Oct;29 Suppl 8:viii485

FOLFIRI3-aflibercept in previously treated patients with metastatic colorectal cancer.

Carola C, Ghiringhelli F, Kim S, André T, Barlet J, Bengrine-Lefevre L, Marijon H, Garcia-Larnicol ML, Borg C, Dainese L, Steuer N, Richa H, Benetkiewicz M, Larsen AK, de Gramont A, Chibaudel B

World J Clin Oncol. 2018 Sep 14;9(5):110-118

Long-term adverse event: inflammatory orbitopathy induced by pembrolizumab in a patient with metastatic melanoma.

Nardin C, Borot S, Beaudoin MA, Cattin F, Puzenat E, Gauthier AS, Schillo F, Borg C, Aubin F

Invest New Drugs. 2018 Aug 25;:

Isolation and characterization of an HLA-DRB1*04-restricted HPV16-E7 T cell receptor for cancer immunotherapy.

Mercier-Letondal P, Marton C, Deschamps M, Ferrand C, Vauchy C, Chenut C, Baguet A, Adotévi O, Borg C, Galaine J, Godet Y

Hum. Gene Ther.. 2018 Aug 23;:

Randomized, double-blind, phase two study of ruxolitinib plus regorafenib in patients with relapsed/refractory metastatic colorectal cancer.

Fogelman D, Cubillo A, García-Alfonso P, Mirón MLL, Nemunaitis J, Flora D, Borg C, Mineur L, Vieitez JM, Cohn A, Saylors G, Assad A, Switzky J, Zhou L, Bendell J

Cancer Med. 2018 Aug 19;:

Docetaxel, cisplatin, and fluorouracil chemotherapy for metastatic or unresectable locally recurrent anal squamous cell carcinoma (Epitopes-HPV02): a multicentre, single-arm, phase 2 study.

Kim S, François E, André T, Samalin E, Jary M, El Hajbi F, Baba-Hamed N, Pernot S, Kaminsky MC, Bouché O, Desrame J, Zoubir M, Ghiringhelli F, Parzy A, De La Fouchardiere C, Smith D, Deberne M, Spehner L, Badet N, Adotevi O, Anota A, Meurisse A, Vernerey D, Taieb J, Vendrely V, Buecher B, Borg C

Lancet Oncol.. 2018 Jul 2;:

Phase II study evaluating trifluridine/tipiracil + bevacizumab and capecitabine + bevacizumab in first-line unresectable metastatic colorectal cancer (mCRC) patients who are non-eligible for intensive therapy (TASCO1): Results of the primary analysis.

Lesniewski-Kmak K, Moiseenko V, Saunders M, Wasan H, Argiles G, Borg C, Creemers G, Fedyanin M, Glynne-Jones R, Pfeiffer P, Punt C, Stroyakovskiy D, Ten Tije A, Van de Wouw A, Kanehisa A, Fougeray R, Busto NL, Amellal N, Van Cutsem E

Ann. Oncol.. 2018 Jun;29 Suppl 5:v108

Baseline splenic volume as a surrogate marker of FOLFIRINOX efficacy in advanced pancreatic carcinoma.

Aarnink A, Richard C, Truntzer C, Vincent J, Bengrine L, Vienot A, Borg C, Ghiringhelli F

Oncotarget. 2018 May 22;9(39):25617-25629

Fluorouracil and bevacizumab plus anakinra for patients with metastatic colorectal cancer refractory to standard therapies (IRAFU): a single-arm phase 2 study.

Isambert N, Hervieu A, Rébé C, Hennequin A, Borg C, Zanetta S, Chevriaux A, Richard C, Derangère V, Limagne E, Blanc J, Bertaut A, Ghiringhelli F

Oncoimmunology. 2018 ;7(9):e1474319

In situ delivery of allogeneic natural killer cell (NK) combined with Cetuximab in liver metastases of gastrointestinal carcinoma: A phase I clinical trial.

Adotevi O, Godet Y, Galaine J, Lakkis Z, Idirene I, Certoux JM, Jary M, Loyon R, Laheurte C, Kim S, Dormoy A, Pouthier F, Barisien C, Fein F, Tiberghien P, Pivot X, Valmary-Degano S, Ferrand C, Morel P, Delabrousse E, Borg C

Oncoimmunology. 2018 ;7(5):e1424673

PD-1/PD-L1 pathway: an adaptive immune resistance mechanism to immunogenic chemotherapy in colorectal cancer.

Dosset M, Vargas TR, Lagrange A, Boidot R, Végran F, Roussey A, Chalmin F, Dondaine L, Paul C, Marie-Joseph EL, Martin F, Ryffel B, Borg C, Adotévi O, Ghiringhelli F, Apetoh L

Oncoimmunology. 2018 ;7(6):e1433981

PD-L1 expression is regulated by both DNA methylation and NF-kB during EMT signaling in non-small cell lung carcinoma.

Asgarova A, Asgarov K, Godet Y, Peixoto P, Nadaradjane A, Boyer-Guittaut M, Galaine J, Guenat D, Mougey V, Perrard J, Pallandre JR, Bouard A, Balland J, Tirole C, Adotevi O, Hendrick E, Herfs M, Cartron PF, Borg C, Hervouet E

Oncoimmunology. 2018 ;7(5):e1423170

SALL4 oncogene is an immunogenic antigen presented in various HLA-DR contexts.

Kroemer M, Spehner L, Mercier-Letondal P, Boullerot L, Kim S, Jary M, Galaine J, Picard E, Ferrand C, Nguyen T, Larosa F, Adotévi O, Godet Y, Borg C

Oncoimmunology. 2018 ;7(4):e1412030

Tumor lymphocyte immune response to preoperative radiotherapy in locally advanced rectal cancer: The LYMPHOREC study.

Mirjolet C, Charon-Barra C, Ladoire S, Arbez-Gindre F, Bertaut A, Ghiringhelli F, Leroux A, Peiffert D, Borg C, Bosset JF, Créhange G

Oncoimmunology. 2018 ;7(3):e1396402

Value of Contrast-Enhanced Ultrasound Quantification Criteria for Identifying Patients not Responding to Bevacizumab-Based Therapy for Colorectal Liver Metastases.

Tranquart F, Dujardin PA, Bouché O, Marcus C, Borg C, Manzoni P, Douillard JY, Labbe-Devilliers C, Terrebonne E, Smith D, Trillaud H, Capitain O, Aubé C, Spano JP, Lucidarme O, Ferru A, Tasu JP, Manfredi S, Bleuzen A, Léger J, Lecomte T

Ultraschall Med. 2017 Dec 12;:

Targeting autophagy inhibits melanoma growth by enhancing NK cells infiltration in a CCL5-dependent manner.

Mgrditchian T, Arakelian T, Paggetti J, Noman MZ, Viry E, Moussay E, Van Moer K, Kreis S, Guerin C, Buart S, Robert C, Borg C, Vielh P, Chouaib S, Berchem G, Janji B

Proc. Natl. Acad. Sci. U.S.A.. 2017 Oct 31;114(44):E9271-E9279

A systematic review of economic evaluation in pancreatic ductal adenocarcinoma.

Gérard C, Fagnoni P, Vienot A, Borg C, Limat S, Daval F, Calais F, Vardanega J, Jary M, Nerich V

Eur. J. Cancer. 2017 Oct;86:207-216

Molecular characteristics of Angiopoietin 2-associated Colorectal Carcinoma.

Jary M, Hasanova R, Faucheu H, Borg C, Feugeas JP

Ann. Oncol.. 2017 Oct;28 Suppl 7:vii31-vii32

Clinical utility of circulating DNA analysis for rapid detection of actionable mutations to select metastatic colorectal patients for anti-EGFR treatment.

Thierry AR, El Messaoudi S, Mollevi C, Raoul JL, Guimbaud R, Pezet D, Artru P, Assenat E, Borg C, Mathonnet M, De La Fouchardière C, Bouché O, Gavoille C, Fiess C, Auzemery B, Meddeb R, Lopez-Crapez E, Sanchez C, Pastor B, Ychou M

Ann. Oncol.. 2017 Sep;28(9):2149-2159

Predictors of responses to immune checkpoint blockade in advanced melanoma.

Jacquelot N, Roberti MP, Enot DP, Rusakiewicz S, Ternès N, Jegou S, Woods DM, Sodré AL, Hansen M, Meirow Y, Sade-Feldman M, Burra A, Kwek SS, Flament C, Messaoudene M, Duong CPM, Chen L, Kwon BS, Anderson AC, Kuchroo VK, Weide B, Aubin F, Borg C, Dalle S, Beatrix O, Ayyoub M, Balme B, Tomasic G, Di Giacomo AM, Maio M, Schadendorf D, Melero I, Dréno B, Khammari A, Dummer R, Levesque M, Koguchi Y, Fong L, Lotem M, Baniyash M, Schmidt H, Svane IM, Kroemer G, Marabelle A, Michiels S, Cavalcanti A, Smyth MJ, Weber JS, Eggermont AM, Zitvogel L

Nat Commun. 2017 Sep;8(1):592

Docetaxel, Cisplatin, and 5-fluorouracil (DCF) chemotherapy in the treatment of metastatic or unresectable locally recurrent anal squamous cell carcinoma: a phase II study of French interdisciplinary GERCOR and FFCD groups (Epitopes-HPV02 study).

Kim S, Jary M, André T, Vendrely V, Buecher B, François E, Bidard FC, Dumont S, Samalin E, Peiffert D, Pernot S, Baba-Hamed N, El Hajbi F, Bouché O, Desrame J, Parzy A, Zoubir M, Louvet C, Bachet JB, Nguyen T, Abdelghani MB, Smith D, De La Fouchardière C, Aparicio T, Bennouna J, Gornet JM, Jacquin M, Bonnetain F, Borg C

BMC Cancer. 2017 Aug;17(1):574

GABARAPL1 tumor suppressive function is independent of its conjugation to autophagosomes in MCF-7 breast cancer cells.

Poillet-Perez L, Jacquet M, Hervouet E, Gauthier T, Fraichard A, Borg C, Pallandre JR, Gonzalez BJ, Ramdani Y, Boyer-Guittaut M, Delage-Mourroux R, Despouy G

Oncotarget. 2017 Aug;8(34):55998-56020

Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib: Patient-focused outcome results from the randomised phase III REACH study.

Chau I, Peck-Radosavljevic M, Borg C, Malfertheiner P, Seitz JF, Park JO, Ryoo BY, Yen CJ, Kudo M, Poon R, Pastorelli D, Blanc JF, Chung HC, Baron AD, Okusaka T, Bowman L, Cui ZL, Girvan AC, Abada PB, Yang L, Zhu AX

Eur. J. Cancer. 2017 Jun;81:17-25

Anal cancer: French Intergroup Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Moureau-Zabotto L, Vendrely V, Abramowitz L, Borg C, Francois E, Goere D, Huguet F, Peiffert D, Siproudhis L, Ducreux M, Bouché O

Dig Liver Dis. 2017 May;:

A new anti-mesothelin antibody targets selectively the membrane-associated form.

Asgarov K, Balland J, Tirole C, Bouard A, Mougey V, Ramos D, Barroso A, Zangiacomi V, Jary M, Kim S, Gonzalez-Pajuelo M, Royer B, de Haard H, Clark A, Wijdenes J, Borg C

MAbs. 2017 Apr;9(3):567-577

Dynamic evaluation of circulating tumour cells in patients with advanced gastric and oesogastric junction adenocarcinoma: Prognostic value and early assessment of therapeutic effects.

Pernot S, Badoual C, Terme M, Castan F, Cazes A, Bouche O, Bennouna J, Francois E, Ghiringhelli F, De La Fouchardiere C, Samalin E, Bachet JB, Borg C, Ducreux M, Marcheteau E, Stanbury T, Gourgou S, Malka D, Taieb J

Eur. J. Cancer. 2017 Apr;79:15-22

How health-related quality of life assessment should be used in advanced colorectal cancer clinical trials.

Bonnetain F, Borg C, Adams RR, Ajani JA, Benson A, Bleiberg H, Chibaudel B, Diaz-Rubio E, Douillard JY, Fuchs CS, Giantonio BJ, Goldberg R, Heinemann V, Koopman M, Labianca R, Larsen AK, Maughan T, Mitchell E, Peeters M, Punt CJA, Schmoll HJ, Tournigand C, de Gramont A

Ann. Oncol.. 2017 Apr;:

Identification of a novel PD-L1 positive solid tumor transplantable in HLA-A0201/DRB10101 transgenic mice.

Rangan L, Galaine J, Boidot R, Hamieh M, Dosset M, Francoual J, Beziaud L, Pallandre JR, Marie Joseph EL, Asgarova A, Borg C, Saati TA, Godet Y, Latouche JB, Valmary-Degano S, Adotévi O

Oncotarget. 2017 Apr;:

Overall Survival Prediction and Usefulness of Second-Line Chemotherapy in Advanced Pancreatic Adenocarcinoma.

Vienot A, Beinse G, Louvet C, de Mestier L, Meurisse A, Fein F, Heyd B, Cleau D, d'Engremont C, Dupont-Gossart AC, Lakkis Z, Tournigand C, Bouché O, Rousseau B, Neuzillet C, Bonnetain F, Borg C, Vernerey D

J. Natl. Cancer Inst.. 2017 Apr;:

A possible association of baseline serum IL-17A concentrations with progression-free survival of metastatic colorectal cancer patients treated with a bevacizumab-based regimen.

Lereclus E, Tout M, Girault A, Baroukh N, Caulet M, Borg C, Bouché O, Ternant D, Paintaud G, Lecomte T, Raoul W

BMC Cancer. 2017 Mar;17(1):220

DNA damage response defect in Williams-Beuren syndrome.

Guenat D, Merla G, Deconinck E, Borg C, Rohrlich PS

Int. J. Mol. Med.. 2017 Mar;39(3):622-628

Somatic mutational spectrum analysis in a prospective series of 104 gastrointestinal stromal tumors.

Guenat D, Deroo O, Magnin S, Chaigneau L, Monnien F, Borg C, Mougin C, Emile JF, Prétet JL

Oncol. Rep.. 2017 Mar;37(3):1671-1681

Prevention of 5-fluorouracil-induced early severe toxicity by pre-therapeutic dihydropyrimidine dehydrogenase deficiency screening: Assessment of a multiparametric approach.

Boisdron-Celle M, Capitain O, Faroux R, Borg C, Metges JP, Galais MP, Kaassis M, Bennouna J, Bouhier-Leporrier K, Francois E, Baumgaertner I, Guerin-Meyer V, Cojocarasu O, Roemer-Becuwe C, Stampfli C, Rosenfeld L, Lecompte T, Berger V, Morel A, Gamelin E

Semin. Oncol.. 2017 Feb;44(1):13-23

[Immuno-oncology and precision medicine: The clinician point of view].

Borg C

Ann Pathol. 2017 Feb;37(1):5-6

Cost-Effectiveness Analysis of Tyrosine Kinase Inhibitors for Patients with Advanced Gastrointestinal Stromal Tumors.

Nerich V, Fleck C, Chaigneau L, Isambert N, Borg C, Kalbacher E, Jary M, Simon P, Pivot X, Blay JY, Limat S

Clin Drug Investig. 2017 Jan;37(1):85-94

DNA damage response defect in Williams-Beuren syndrome.

Guenat D, Merla G, Deconinck E, Borg C, Rohrlich PS

Int. J. Mol. Med.. 2017 Jan;:

Fungal peptides from pneumonitis hypersensitivity etiologic agents are able to induce specific cellular immune response.

Bellanger AP, Lignon T, Godet Y, Rognon B, Reboux G, Gbaguidi-Haore H, Borg C, Millon L

J. Immunol. Methods. 2017 Jan;440:67-73

NKp30 isoforms and NKp30 ligands are predictive biomarkers of response to imatinib mesylate in metastatic GIST patients.

Rusakiewicz S, Perier A, Semeraro M, Pitt JM, Pogge von Strandmann E, Reiners KS, Aspeslagh S, Pipéroglou C, Vély F, Ivagnes A, Jegou S, Halama N, Chaigneau L, Validire P, Christidis C, Perniceni T, Landi B, Berger A, Isambert N, Domont J, Bonvalot S, Terrier P, Adam J, Coindre JM, Emile JF, Poirier-Colame V, Chaba K, Rocha B, Caignard A, Toubert A, Enot D, Koch J, Marabelle A, Lambert M, Caillat-Zucman S, Leyvraz S, Auclair C, Vivier E, Eggermont A, Borg C, Blay JY, Le Cesne A, Mir O, Zitvogel L

Oncoimmunology. 2017 ;6(1):e1137418

Perioperative docetaxel, cisplatin, and 5-fluorouracil compared to standard chemotherapy for resectable gastroesophageal adenocarcinoma.

Kim S, Paget-Bailly S, Messager M, Nguyen T, Mathieu P, Lamfichekh N, Fein F, Fratté S, Cléau D, Lakkis Z, Jary M, Sakek N, Jacquin M, Foubert A, Bonnetain F, Mariette C, Fiteni F, Borg C

Eur J Surg Oncol. 2017 Jan;43(1):218-225

Prognostic impact of the expression of NCR1 and NCR3 NK cell receptors and PD-L1 on advanced non-small cell lung cancer.

Fend L, Rusakiewicz S, Adam J, Bastien B, Caignard A, Messaoudene M, Iribarren C, Cremer I, Marabelle A, Borg C, Semeraro M, Barraud L, Limacher JM, Eggermont A, Kroemer G, Zitvogel L

Oncoimmunology. 2017 ;6(1):e1163456

Bevacizumab Pharmacokinetics Influence Overall and Progression-Free Survival in Metastatic Colorectal Cancer Patients.

Caulet M, Lecomte T, Bouché O, Rollin J, Gouilleux-Gruart V, Azzopardi N, Léger J, Borg C, Douillard JY, Manfredi S, Smith D, Capitain O, Ferru A, Moussata D, Terrebone E, Paintaud G, Ternant D

Clin Pharmacokinet. 2016 Nov;55(11):1381-1394

Docetaxel, Cisplatin, and 5-Fluorouracil as perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma.

Fiteni F, Paget-Bailly S, Messager M, N'Guyen T, Lakkis Z, Mathieu P, Lamfichekh N, Picard A, Benzidane B, Cléau D, Bonnetain F, Borg C, Mariette C, Kim S

Cancer Med. 2016 Nov;5(11):3085-3093

Prognostic value of baseline seric Syndecan-1 in initially unresectable metastatic colorectal cancer patients: a simple biological score.

Jary M, Lecomte T, Bouché O, Kim S, Dobi E, Queiroz L, Ghiringhelli F, Etienne H, Léger J, Godet Y, Balland J, Lakkis Z, Adotevi O, Bonnetain F, Borg C, Vernerey D

Int. J. Cancer. 2016 Nov;139(10):2325-35

Additive value of pre-operative and one-month post-operative lymphocyte count for death-risk stratification in patients with resectable pancreatic cancer: a multicentric study.

d'Engremont C, Vernerey D, Pointet AL, Simone G, Fein F, Heyd B, Koch S, Vuitton L, Kim S, Jary M, Lamfichek N, Turco C, Lakkis Z, Berger A, Bonnetain F, Taieb J, Bachellier P, Borg C

BMC Cancer. 2016 Oct;16(1):823

Heparan Sulfate Proteoglycans Promote Telomerase Internalization and MHC Class II Presentation on Dendritic Cells.

Galaine J, Kellermann G, Guillaume Y, Boidot R, Picard E, Loyon R, Queiroz L, Boullerot L, Beziaud L, Jary M, Mansi L, André C, Lethier L, Ségal-Bendirdjian E, Borg C, Godet Y, Adotévi O

J. Immunol.. 2016 Sep;197(5):1597-608

Complete Response to Aflibercept-FOLFIRI in One Patient With Colorectal Cancer Refractory to Bevacizumab-FOLFOX: A Possible Autocrine Vascular Endothelial Growth Factor Receptor 2-Related Mechanism.

Kim S, Cayre A, Jary M, Jacquin M, Arbez-Gindre F, Fein F, Lakkis Z, Nguyen T, Borg C

Clin Colorectal Cancer. 2016 Aug;:

Exposure to hypomethylating agent, 5-azacytidine, may improve iCasp9 suicide gene therapy for treating GvHD in allografts.

Bôle-Richard E, Gamonet C, Certoux JM, Idirene I, Larosa F, Deconinck E, Mosseley AM, Tiberghien P, Borg C, Ferrand C, Deschamps M

Gene Ther.. 2016 Aug;23(8-9):664-72

Metronomic cyclophosphamide therapy in hormone-naive patients with non-metastatic biochemical recurrent prostate cancer: a phase II trial.

Calcagno F, Mouillet G, Adotevi O, Maurina T, Nguyen T, Montcuquet P, Curtit E, Kleinclauss F, Pivot X, Borg C, Thiery-Vuillemin A

Med. Oncol.. 2016 Aug;33(8):89

Nanovectorization of DNA Through Cells Using Protamine Complexation.

Boukari K, Caoduro C, Kacem R, Skandrani N, Borg C, Boulahdour H, Gharbi T, Delage-Mourroux R, Hervouet E, Pudlo M, Picaud F

J. Membr. Biol.. 2016 Aug;249(4):493-501

Selective Inhibition of STAT3 with Respect to STAT1: Insights from Molecular Dynamics and Ensemble Docking Simulations.

Yesylevskyy SO, Ramseyer C, Pudlo M, Pallandre JR, Borg C

J Chem Inf Model. 2016 Aug;56(8):1588-96

IL-21-Induced MHC Class II+ NK Cells Promote the Expansion of Human Uncommitted CD4+ Central Memory T Cells in a Macrophage Migration Inhibitory Factor-Dependent Manner.

Loyon R, Picard E, Mauvais O, Queiroz L, Mougey V, Pallandre JR, Galaine J, Mercier-Letondal P, Kellerman G, Chaput N, Wijdenes J, Adotévi O, Ferrand C, Romero P, Godet Y, Borg C

J. Immunol.. 2016 Jul;197(1):85-96

Rapalogs Efficacy Relies on the Modulation of Antitumor T-cell Immunity.

Beziaud L, Mansi L, Ravel P, Marie-Joseph EL, Laheurte C, Rangan L, Bonnefoy F, Pallandre JR, Boullerot L, Gamonet C, Vrecko S, Queiroz L, Maurina T, Mouillet G, Hon TN, Curtit E, Royer B, Gaugler B, Bayry J, Tartour E, Thiery-Vuillemin A, Pivot X, Borg C, Godet Y, Adotévi O

Cancer Res.. 2016 Jul;76(14):4100-12

Immunophenotyping of Stage III Melanoma Reveals Parameters Associated with Patient Prognosis.

Jacquelot N, Roberti MP, Enot DP, Rusakiewicz S, Semeraro M, Jégou S, Flores C, Chen L, Kwon BS, Borg C, Weide B, Aubin F, Dalle S, Kohrt H, Ayyoub M, Kroemer G, Marabelle A, Cavalcanti A, Eggermont A, Zitvogel L

J. Invest. Dermatol.. 2016 May;136(5):994-1001

Immunoprevalence and magnitude of HLA-DP4 versus HLA-DR-restricted spontaneous CD4(+) Th1 responses against telomerase in cancer patients.

Laheurte C, Galaine J, Beziaud L, Dosset M, Kerzerho J, Jacquemard C, Gaugler B, Ferrand C, Dormoy A, Aubin F, Jacoulet P, Westeel V, Borg C, Tartour E, Godet Y, Maillère B, Adotévi O

Oncoimmunology. 2016 May;5(5):e1137416

Efficacy, Safety and Cost of Regorafenib in Patients with Metastatic Colorectal Cancer in French Clinical Practice.

Calcagno F, Lenoble S, Lakkis Z, Nguyen T, Limat S, Borg C, Jary M, Kim S, Nerich V

Clin Med Insights Oncol. 2016 ;10:59-66

Tumor control by human cytomegalovirus in a murine model of hepatocellular carcinoma.

Kumar A, Coquard L, Pasquereau S, Russo L, Valmary-Degano S, Borg C, Pothier P, Herbein G

Mol Ther Oncolytics. 2016 ;3:16012

Chemotherapy-induced antitumor immunity requires formyl peptide receptor 1.

Vacchelli E, Ma Y, Baracco EE, Sistigu A, Enot DP, Pietrocola F, Yang H, Adjemian S, Chaba K, Semeraro M, Signore M, De Ninno A, Lucarini V, Peschiaroli F, Businaro L, Gerardino A, Manic G, Ulas T, Günther P, Schultze JL, Kepp O, Stoll G, Lefebvre C, Mulot C, Castoldi F, Rusakiewicz S, Ladoire S, Apetoh L, Bravo-San Pedro JM, Lucattelli M, Delarasse C, Boige V, Ducreux M, Delaloge S, Borg C, André F, Schiavoni G, Vitale I, Laurent-Puig P, Mattei F, Zitvogel L, Kroemer G

Science. 2015 Nov;350(6263):972-8

Novel aminotetrazole derivatives as selective STAT3 non-peptide inhibitors.

Pallandre JR, Borg C, Rognan D, Boibessot T, Luzet V, Yesylevskyy S, Ramseyer C, Pudlo M

Eur J Med Chem. 2015 Sep 1;103:163-174

[Anti-angiogenic treatments in metastatic colorectal cancer: Does a continuous angiogenic blockade make sense?].

Jary M, Borg C, Bouche O, Kim S, Andre T, Bennouna J

Bull Cancer. 2015 Sep;102(9):758-71

CD20 alternative splicing isoform generates immunogenic CD4 helper T epitopes.

Vauchy C, Gamonet C, Ferrand C, Daguindau E, Galaine J, Beziaud L, Chauchet A, Henry Dunand CJ, Deschamps M, Rohrlich PS, Borg C, Adotevi O, Godet Y

Int J Cancer. 2015 Jul 1;137(1):116-26

[New immunotherapeutic approches in oncology and hematology].

Kroemer M, Turco C, Galaine J, Deschamps, Borg C

Transfus Clin Biol. 2015 Jun 8. pii: S1246-7820(15)00031-2

P7.02The clinical potential of ARGX-111, an afucosylated anti-MET antibody, in hematological malignancies and suppression of metastasis.

Hanssens V, De Jonge N, Hultberg A, Borg C, Michieli P, Dreier T, de Haard H, Thibault A

Ann Oncol. 2015 Mar;26 Suppl 2:ii31

Investigating the impact of Echinococcus multilocularis vesicular fluid on human cells from healthy blood donors.

Bellanger AP, Pallandre JR, Gbaguidi-Haore H, Knapp J, Malezieux N, Lignon T, Borg C, Millon L

J Immunol Methods. 2015 Feb;417:52-9

Gemcitabine-Induced Pulmonary Toxicity: A Case Report of Pulmonary Veno-Occlusive Disease.

Turco C, Jary M, Kim S, Moltenis M, Degano B, Manzoni P, Nguyen T, Genet B, Rabier MB, Heyd B, Borg C

Clin Med Insights Oncol. 2015 Sep 1;9:75-9

Interest of Tumor-Specific CD4 T Helper 1 Cells for Therapeutic Anticancer Vaccine.

Galaine J, Borg C, Godet Y, Adotevi O

Vaccines (Basel). 2015 Jun 30;3(3):490-502

New CD20 alternative splice variants: molecular identification and differential expression within hematological B cell malignancies.

Gamonet C, Bole-Richard E, Delherme A, Aubin F, Toussirot E, Garnache-Ottou F, Godet Y, Ysebaert L, Tournilhac O, Caroline D, Larosa F, Deconinck E, Saas P, Borg C, Deschamps M, Ferrand C

Exp Hematol Oncol. 2015 ;5:7

Primary Linitis Plastica of the Rectum: Focus on Magnetic Resonance Imaging Patterns and Treatment Options.

Boustani J, Kim S, Lescut N, Lakkis Z, de Billy M, Arbez-Gindre F, Jary M, Borg C, Bosset JF

Am J Case Rep. 2015 Aug 31;16:581-5

Prognostic Value of Angiopoietin-2 for death risk stratification in Patients with Metastatic Colorectal Carcinoma.

Jary M, Vernerey D, Lecomte T, Dobi E, Ghiringhelli F, Monnien F, Godet Y, Kim S, Bouche O, Fratte S, Goncalves A, Leger J, Queiroz L, Adotevi O, Bonnetain F, Borg C

Cancer Epidemiol Biomarkers Prev. 2015 Jan 12. pii: cebp.1059.2014.

The impact of taxane-based preoperative chemotherapy in gastroesophageal signet ring cell adenocarcinomas.

Kim S, Fiteni F, Paget-Bailly S, Ghiringhelli F, Lakkis Z, Jary M, Fein F, Bonnetain F, Mariette C, Borg C

J Hematol Oncol. 2015 May 15;8(1):52

Time to health-related quality of life score deterioration as a modality of longitudinal analysis for health-related quality of life studies in oncology: do we need RECIST for quality of life to achieve standardization?

Anota A, Hamidou Z, Paget-Bailly S, Chibaudel B, Bascoul-Mollevi C, Auquier P, Westeel V, Fiteni F, Borg C, Bonnetain F

Qual Life Res. 2015 Jan;24(1):5-18

Cisplatin/gemcitabine or oxaliplatin/gemcitabine in the treatment of advanced biliary tract cancer: a systematic review.

Fiteni F, Nguyen T, Vernerey D, Paillard MJ, Kim S, Demarchi M, Fein F, Borg C, Bonnetain F, Pivot X

Cancer Med. 2014 Dec;3(6):1502-11

Constitutional and somatic deletions of the Williams-Beuren syndrome critical region in Non-Hodgkin inverted question marks Lymphoma.

Guenat D, Quentin S, Rizzari C, Lundin C, Coliva T, Edery P, Fryssira H, Bermont L, Ferrand C, Soulier J, Christophe B, Rohrlich PS

J Hematol Oncol. 2014 Nov 7;7(1):82.

Pathological response and safety of two neoadjuvant strategies with bevacizumab in MRI-defined locally advanced T3 resectable rectal cancer: a randomized, noncomparative phase II study.

Borg C, Andre T, Mantion G, Boudghene F, Mornex F, Maingon P, Adenis A, Azria D, Piutti M, Morsli O, Bosset JF

Ann Oncol. 2014 Nov;25(11):2205-10

Phase II multicentre study of efficacy and feasibility of dose-intensified preoperative weekly cisplatin, epirubicin, and paclitaxel (PET) in resectable gastroesophageal cancer.

Jary M, Ghiringhelli F, Jacquin M, Fein F, Nguyen T, Cleau D, Nerich V, El Gani M, Mathieu P, Valmary-Degano S, Arnould L, Lassabe C, Lamfichekh N, Fratte S, Paget-Bailly S, Bonnetain F, Borg C, Kim S

Cancer Chemother Pharmacol. 2014 Jul;74(1):141-50

Bevacizumab efficacy in metastatic colorectal cancer is dependent on primary tumor resection.

Ghiringhelli F, Bichard D, Limat S, Lorgis V, Vincent J, Borg C, Berthou J, Orry D, Ortega-Deballon P, Lakkis Z, Facy O, Heyd B, Rat P, Nerich V, Ladoire S

Ann Surg Oncol. 2014 May;21(5):1632-40

In vivo proof of concept of adoptive immunotherapy for hepatocellular carcinoma using allogeneic suicide gene-modified killer cells.

Leboeuf C, Mailly L, Wu T, Bour G, Durand S, Brignon N, Ferrand C, Borg C, Tiberghien P, Thimme R, Pessaux P, Marescaux J, Baumert TF, Robinet E

Mol Ther. 2014 Mar;22(3):634-44

Endpoints in cancer clinical trials.

Fiteni F, Westeel V, Pivot X, Borg C, Vernerey D, Bonnetain F

J Visc Surg. 2014 Feb;151(1):17-22

Advanced biliary tract carcinomas: a retrospective multicenter analysis of first and second-line chemotherapy.

Fiteni F, Jary M, Monnien F, Nguyen T, Beohou E, Demarchi M, Dobi E, Fein F, Cleau D, Fratte S, Nerich V, Bonnetain F, Pivot X, Borg C, Kim S

BMC Gastroenterol. 2014 Aug 13;14:143

Constitutional and somatic deletions of the Williams-Beuren syndrome critical region in non-Hodgkin lymphoma.

Guenat D, Quentin S, Rizzari C, Lundin C, Coliva T, Edery P, Fryssira H, Bermont L, Ferrand C, Soulier J, Borg C, Rohrlich PS

J Hematol Oncol. 2014 Nov 7;7:82

Immunogenicity evaluation of a rationally designed polytope construct encoding HLA-A*0201 restricted epitopes derived from Leishmania major related proteins in HLA-A2/DR1 transgenic mice: steps toward polytope vaccine.

Seyed N, Taheri T, Vauchy C, Dosset M, Godet Y, Eslamifar A, Sharifi I, Adotevi O, Borg C, Rohrlich PS, Rafati S

PLoS One. 2014 Oct 13;9(10):e108848

Immunomodulatory effects of everolimus in a long responsive patient with metastatic renal cell carcinoma.

Thiery-Vuillemin A, Laheurte C, Mansi L, Royer B, Pivot X, Borg C, Adotevi O

J Immunother. 2014 Jan;37(1):51-4

QSOX1 inhibits autophagic flux in breast cancer cells.

Poillet L, Pernodet N, Boyer-Guittaut M, Adami P, Borg C, Jouvenot M, Delage-Mourroux R, Despouy G

PLoS One. 2014 Jan 24;9(1):e86641

DCF (docetaxel, cisplatin and 5-fluorouracil) chemotherapy is a promising treatment for recurrent advanced squamous cell anal carcinoma.

Kim S, Jary M, Mansi L, Benzidane B, Cazorla A, Demarchi M, Nguyen T, Kaliski A, Delabrousse E, Bonnetain F, Letondal P, Bosset JF, Valmary-Degano S, Borg C

Ann Oncol. 2013 Dec;24(12):3045-50

Human monocyte-derived dendritic cells exposed to microorganisms involved in hypersensitivity pneumonitis induce a Th1-polarized immune response.

Bellanger AP, Pallandre JR, Borg C, Loeffert S, Gbaguidi-Haore H, Millon L

Clin Vaccine Immunol. 2013 Aug;20(8):1133-42

Metronomic cyclophosphamide: an alternative treatment for hepatic epithelioid hemangioendothelioma.

Lakkis Z, Kim S, Delabrousse E, Jary M, Nguyen T, Mantion G, Heyd B, Lassabe C, Borg C

J Hepatol. 2013 Jun;58(6):1254-7

Targeting antitumor CD4 helper T cells with universal tumor-reactive helper peptides derived from telomerase for cancer vaccine.

Adotevi O, Dosset M, Galaine J, Beziaud L, Godet Y, Borg C

Hum Vaccin Immunother. 2013 May;9(5):1073-7

CD4 lymphopenia to identify end-of-life metastatic cancer patients.

Peron J, Cropet C, Tredan O, Bachelot T, Ray-Coquard I, Clapisson G, Chabaud S, Philip I, Borg C, Cassier P, Labidi Galy I, Sebban C, Perol D, Biron P, Caux C, Menetrier-Caux C, Blay JY

Eur J Cancer. 2013 Mar;49(5):1080-9

Economic impact of prescribing error prevention with computerized physician order entry of injectable antineoplastic drugs.

Nerich V, Borg C, Villanueva C, Thiery-Vuillemin A, Helias P, Rohrlich PS, Demarchi M, Pivot X, Limat S

J Oncol Pharm Pract. 2013 Mar;19(1):8-17

Impact of STAT3 phosphorylation on the clinical effectiveness of anti-EGFR-based therapy in patients with metastatic colorectal cancer.

Dobi E, Monnien F, Kim S, Ivanaj A, N'Guyen T, Demarchi M, Adotevi O, Thierry-Vuillemin A, Jary M, Kantelip B, Pivot X, Godet Y, Degano SV, Borg C

Clin Colorectal Cancer. 2013 Mar;12(1):28-36

Influence of fractalkine receptor gene polymorphisms V249I-T280M on cancer occurrence after renal transplantation.

Courivaud C, Bamoulid J, Loupy A, Deschamps M, Ferrand C, Simula-Faivre D, Tiberghien P, Chalopin JM, Legendre C, Thervet E, Borg C, Saas P, Ducloux D

Transplantation. 2013 Mar;95(5):728-32

Bifractionated CPT-11 with LV5FU2 infusion (FOLFIRI-3) in combination with bevacizumab: clinical outcomes in first-line metastatic colorectal cancers according to plasma angiopoietin-2 levels.

Kim S, Dobi E, Jary M, Monnien F, Curtit E, Nguyen T, Lakkis Z, Heyd B, Fratte S, Cleau D, Lamfichekh N, Nerich V, Guiu B, Demarchi M, Borg C

BMC Cancer. 2013 Dec 27;13:611

Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial.

Bennouna J, Sastre J, Arnold D, Österlund P, Greil R, Van Cutsem E, von Moos R, Viéitez JM, Bouché O, Borg C, Steffens CC, Alonso-Orduña V, Schlichting C, Reyes-Rivera I, Bendahmane B, André T, Kubicka S,

Lancet Oncol.. 2013 Jan;14(1):29-37

Is preexisting antitumor CD4 T cell response indispensable for the chemotherapy induced immune regression of cancer?

Godet Y, Dosset M, Borg C, Adotevi O

Oncoimmunology. 2012 Dec 1;1(9):1617-1619.

Universal cancer peptide-based therapeutic vaccine breaks tolerance against telomerase and eradicates established tumor.

Dosset M, Godet Y, Vauchy C, Beziaud L, Lone YC, Sedlik C, Liard C, Levionnois E, Clerc B, Sandoval F, Daguindau E, Wain-Hobson S, Tartour E, Langlade-Demoyen P, Borg C, Adotevi O

Clin Cancer Res. 2012 Nov 15;18(22):6284-95

Cytomegalovirus exposure, immune exhaustion and cancer occurrence in renal transplant recipients.

Courivaud C, Bamoulid J, Gaugler B, Roubiou C, Arregui C, Chalopin JM, Borg C, Tiberghien P, Woronoff-Lemsi MC, Saas P, Ducloux D

Transpl Int. 2012 Sep;25(9):948-55

[Immunotherapy: an emerging strategies against prostate castration resistant cancer].

Mansi L, Thiery-Vuillemin A, Kalbacher E, Nguyen T, Maurina T, Nallet J, Kim S, Borg C, Kleinclauss F, Pivot X, Adotevi O

Bull Cancer. 2012 Jul;99 Suppl 1:S57-65

Analysis of spontaneous tumor-specific CD4 T-cell immunity in lung cancer using promiscuous HLA-DR telomerase-derived epitopes: potential synergistic effect with chemotherapy response.

Godet Y, Fabre E, Dosset M, Lamuraglia M, Levionnois E, Ravel P, Benhamouda N, Cazes A, Le Pimpec-Barthes F, Gaugler B, Langlade-Demoyen P, Pivot X, Saas P, Maillere B, Tartour E, Borg C, Adotevi O

Clin Cancer Res. 2012 May 15;18(10):2943-53

Loss of central and peripheral CD8+ T-cell tolerance to HFE in mouse models of human familial hemochromatosis.

Boucherma R, Kridane-Miledi H, Vives FL, Vauchy C, Borg C, Kleinclauss F, Fiette L, Tiberghien P, Lemonnier FA, Rohrlich PS, Huetz F

Eur J Immunol. 2012 Apr;42(4):851-62

Bevacizumab combined with chemotherapy in the second-line treatment of metastatic colorectal cancer: results from the phase II BEVACOLOR study.

Bennouna J, Borg C, Delord JP, Husseini F, Trillet-Lenoir V, Faroux R, Francois E, Ychou M, Goldwasser F, Bouche O, Senellart H, Kraemer S, Douillard JY

Clin Colorectal Cancer. 2012 Mar;11(1):38-44

Stat3 and Gfi-1 transcription factors control Th17 cell immunosuppressive activity via the regulation of ectonucleotidase expression.

Chalmin F, Mignot G, Bruchard M, Chevriaux A, Vegran F, Hichami A, Ladoire S, Derangere V, Vincent J, Masson D, Robson SC, Eberl G, Pallandre JR, Borg C, Ryffel B, Apetoh L, Rebe C, Ghiringhelli F

Immunity. 2012 Mar 23;36(3):362-73

High expression of QSOX1 reduces tumorogenesis, and is associated with a better outcome for breast cancer patients.

Pernodet N, Hermetet F, Adami P, Vejux A, Descotes F, Borg C, Adams M, Pallandre JR, Viennet G, Esnard F, Jouvenot M, Despouy G

Breast Cancer Res. 2012 Oct 25;14(5):R136

A multiplex SNaPshot assay as a rapid method for detecting KRAS and BRAF mutations in advanced colorectal cancers.

Magnin S, Viel E, Baraquin A, Valmary-Degano S, Kantelip B, Pretet JL, Mougin C, Bigand M, Girardo B, Borg C, Ferrand C

J Mol Diagn. 2011 Sep;13(5):485-92

Thymic function, anti-thymocytes globulins, and cancer after renal transplantation.

Ducloux D, Bamoulid J, Courivaud C, Gaugler B, Rebibou JM, Ferrand C, Chalopin JM, Borg C, Tiberghien P, Saas P

Transpl Immunol. 2011 Jul;25(1):56-60

Complete histologic response induced by sorafenib in advanced hepatocellular carcinoma: a case report.

Curtit E, Thiery-Vuillemin A, Nguyen T, Heyd B, Pivot X, Di Martino V, Borg C

J. Clin. Oncol.. 2011 Apr;29(12):e330-2

Novel role for STAT3 in transcriptional regulation of NK immune cell targeting receptor MICA on cancer cells.

Bedel R, Thiery-Vuillemin A, Grandclement C, Balland J, Remy-Martin JP, Kantelip B, Pallandre JR, Pivot X, Ferrand C, Tiberghien P, Borg C

Cancer Res. 2011 Mar 1;71(5):1615-26

Neuropilin-2 expression promotes TGF-beta1-mediated epithelial to mesenchymal transition in colorectal cancer cells.

Grandclement C, Pallandre JR, Valmary Degano S, Viel E, Bouard A, Balland J, Remy-Martin JP, Simon B, Rouleau A, Boireau W, Klagsbrun M, Ferrand C, Borg C

PLoS One. 2011;6(7):e20444

Neuropilins: a new target for cancer therapy.

Grandclement C, Borg C

Cancers (Basel). 2011 Apr 8;3(2):1899-928

Computerized physician order entry of injectable antineoplastic drugs: an epidemiologic study of prescribing medication errors.

Nerich V, Limat S, Demarchi M, Borg C, Rohrlich PS, Deconinck E, Westeel V, Villanueva C, Woronoff-Lemsi MC, Pivot X

Int J Med Inform. 2010 Oct;79(10):699-706.

Prognostic value of phosphorylated STAT3 in advanced rectal cancer: a study from 104 French patients included in the EORTC 22921 trial.

Monnien F, Zaki H, Borg C, Mougin C, Bosset JF, Mercier M, Arbez-Gindre F, Kantelip B

J Clin Pathol. 2010 Oct;63(10):873-8.

Identification of an alternative CD20 transcript variant in B-cell malignancies coding for a novel protein associated to rituximab resistance.

Henry C, Deschamps M, Rohrlich PS, Pallandre JR, Remy-Martin JP, Callanan M, Traverse-Glehen A, GrandClement C, Garnache-Ottou F, Gressin R, Deconinck E, Salles G, Robinet E, Tiberghien P, Borg C, Ferrand C

Blood. 2010 Mar 25;115(12):2420-9

Membrane-associated Hsp72 from tumor-derived exosomes mediates STAT3-dependent immunosuppressive function of mouse and human myeloid-derived suppressor cells.

Chalmin F, Ladoire S, Mignot G, Vincent J, Bruchard M, Remy-Martin JP, Boireau W, Rouleau A, Simon B, Lanneau D, De Thonel A, Multhoff G, Hamman A, Martin F, Chauffert B, Solary E, Zitvogel L, Garrido C, Ryffel B, Borg C, Apetoh L, Rebe C, Ghiringhelli F

J Clin Invest. 2010 Feb 1;120(2):457-71

Natural killer cell IFN-gamma levels predict long-term survival with imatinib mesylate therapy in gastrointestinal stromal tumor-bearing patients.

Ménard C, Blay JY, Borg C, Michiels S, Ghiringhelli F, Robert C, Nonn C, Chaput N, Taïeb J, Delahaye NF, Flament C, Emile JF, Le Cesne A, Zitvogel L

Cancer Res.. 2009 Apr;69(8):3563-9

Dendritic cell and natural killer cell cross-talk: a pivotal role of CX3CL1 in NK cytoskeleton organization and activation.

Pallandre JR, Krzewski K, Bedel R, Ryffel B, Caignard A, Rohrlich PS, Pivot X, Tiberghien P, Zitvogel L, Strominger JL, Borg C

Blood. 2008 Dec 1;112(12):4420-4

Influence of capecitabine absorption on its metabolites pharmacokinetics: a bioequivalence study.

Chaigneau L, Royer B, Montange D, Nguyen T, Maurina T, Villanueva C, Demarchi M, Borg C, Fagnoni-Legat C, Kantelip JP, Pivot X

Ann Oncol. 2008 Nov;19(11):1980-1.

Sirolimus enhances the effect of apoptotic cell infusion on hematopoietic engraftment and tolerance induction.

Bonnefoy F, Masson E, Perruche S, Marandin A, Borg C, Radlovic A, Shipman B, Tiberghien P, Saas P, Kleinclauss F

Leukemia. 2008 Jul;22(7):1430-4

EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer.

Sobrero AF, Maurel J, Fehrenbacher L, Scheithauer W, Abubakr YA, Lutz MP, Vega-Villegas ME, Eng C, Steinhauer EU, Prausova J, Lenz HJ, Borg C, Middleton G, Kroning H, Luppi G, Kisker O, Zubel A, Langer C, Kopit J, Burris HA 3rd

J Clin Oncol. 2008 May 10;26(14):2311-9

Ixabepilone, a novel epothilone analog in the treatment of breast cancer.

Pivot X, Villanueva C, Chaigneau L, Nguyen T, Demarchi M, Maurina T, Stein U, Borg C

Expert Opin Investig Drugs. 2008 Apr;17(4):593-9.

A retrospective study of bifractionated CPT-11 with LF5FU infusion (FOLFIRI-3) in colorectal cancer patients pretreated with oxaliplatin and CPT-11 containing chemotherapies.

Viel E, Demarchi MF, Chaigneau L, Nguyen T, Legat C, Stein U, Thiery-Vuillemin A, Limat S, Pivot X, Borg C

Am J Clin Oncol. 2008 Feb;31(1):89-94.

Human leukocyte antigen-G5 secretion by human mesenchymal stem cells is required to suppress T lymphocyte and natural killer function and to induce CD4+CD25highFOXP3+ regulatory T cells.

Selmani Z, Naji A, Zidi I, Favier B, Gaiffe E, Obert L, Borg C, Saas P, Tiberghien P, Rouas-Freiss N, Carosella ED, Deschaseaux F

Stem Cells. 2008 Jan;26(1):212-22

Role of STAT3 in CD4(+)CD25(+)FOXP3(+) regulatory lymphocyte generation: Implications in graft-versus-host disease and antitumor immunity

Pallandre JR, Brillard E, Crehange G, Radlovic A, Remy-Martin JP, Saas P, Rohrlich PS, Pivot X, Ling XA, Tiberghien P, Borg C

J Immunol. 2007 Dec 1;179(11):7593-604.

Natural killer cells prevent CD28-mediated Foxp3 transcription in CD4(+)CD25(-) T lymphocytes

Brillard E, Pallandre JR, Chalmers D, Ryffel B, Radlovic A, Seilles E, Rohrlich PS, Pivot X, Tiberghien P, Saas P, Borg C

Exp Hematol. 2007 Mar;35(3):416-25.

[Prognostic factors for febrile neutropenia].

Ray-Coquard I, Borg C, Bachelot T, Fayette J, Zufferey L, Guastalla JP, Ghesquiere H, Blay JY, Sebban C, Marec-Berard P, Biron P

Bull Cancer. 2006 May 1;93(5):501-6.

Dendritic cell-NK cell cross-talk: regulation and physiopathology.

Zitvogel L, Terme M, Borg C, Trinchieri G

Curr Top Microbiol Immunol. 2006;298:157-74.

BCR/ABL promotes dendritic cell-mediated natural killer cell activation.

Terme M, Borg C, Guilhot F, Masurier C, Flament C, Wagner EF, Caillat-Zucman S, Bernheim A, Turhan AG, Caignard A, Zitvogel L

Cancer Res.. 2005 Jul;65(14):6409-17

Vaccination of metastatic melanoma patients with autologous dendritic cell (DC) derived-exosomes: results of thefirst phase I clinical trial.

Escudier B, Dorval T, Chaput N, Andre F, Caby MP, Novault S, Flament C, Leboulaire C, Borg C, Amigorena S, Boccaccio C, Bonnerot C, Dhellin O, Movassagh M, Piperno S, Robert C, Serra V, Valente N, Le Pecq JB, Spatz A, Lantz O, Tursz T, Angevin E, Zitvogel L

J Transl Med. 2005 Mar 2;3(1):10.

CD4 lymphopenia as a risk factor for febrile neutropenia and early death after cytotoxic chemotherapy in adult patients with cancer.

Borg C, Ray-Coquard I, Philip I, Clapisson G, Bendriss-Vermare N, Menetrier-Caux C, Sebban C, Biron P, Blay JY

Cancer. 2004 Dec 1;101(11):2675-80.

NK cell activation by dendritic cells (DCs) requires the formation of a synapse leading to IL-12 polarization in DCs.

Borg C, Jalil A, Laderach D, Maruyama K, Wakasugi H, Charrier S, Ryffel B, Cambi A, Figdor C, Vainchenker W, Galy A, Caignard A, Zitvogel L

Blood. 2004 Nov 15;104(10):3267-75

Novel mode of action of c-kit tyrosine kinase inhibitors leading to NK cell-dependent antitumor effects.

Borg C, Terme M, Taïeb J, Ménard C, Flament C, Robert C, Maruyama K, Wakasugi H, Angevin E, Thielemans K, Le Cesne A, Chung-Scott V, Lazar V, Tchou I, Crépineau F, Lemoine F, Bernard J, Fletcher JA, Turhan A, Blay JY, Spatz A, Emile JF, Heinrich MC, Mécheri S, Tursz T, Zitvogel L

J. Clin. Invest.. 2004 Aug;114(3):379-88

X-chromosome genetics and human cancer.

Spatz A, Borg C, Feunteun J

Nat. Rev. Cancer. 2004 Aug;4(8):617-29